Cancer

Neurona Therapeutics Appoints James Stutz as Chief Financial Officer and Chief Business Officer

SAN FRANCISCO, July 31, 2023 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for…

1 year ago

Immutep Quarterly Activities Report Q4 FY23

Media Release Late-stage & registrational trial progress: TACTI-004 Phase III - Positive feedback received from US FDA for planned registrational…

1 year ago

Immutep to Present Overall Survival Data in 1st Line Non-Small Cell Lung Cancer Accepted for Oral Presentation at ESMO Congress 2023

Media Release Mini Oral presentation will include data from TACTI-002 Phase II trial evaluating chemotherapy-free IO combination of efti plus…

1 year ago

Spago Nanomedical interim report January-June 2023

LUND, SE / ACCESSWIRE / July 31, 2023 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F) Tumorad® into clinicJANUARY - JUNE IN BRIEFNet…

1 year ago

Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS

89% and 84% of patients were maintained on ≥12- and ≥16-week dosing intervals, respectively, throughout the two-year period, while sustaining their…

1 year ago

Beauty-Stem Biomedical Holds Successful CD34 Stem Cell Medical Symposium Exploring Regenerative Trend ‘CD34 Health Deposit’

Beauty-Stem Biomedical's Medical Seminar Unveils Remarkable Link Between CD34 Stem Cells and Human Well-Being: Regeneration, Immune Enhancement and HematopoiesisLOS ANGELES,…

1 year ago

Unify Medical Announces Know-How Agreement With Mayo Clinic for Fluorescence-Guided Visualization

Unify Medical, Inc., a privately-held, smart, surgical visualization technology company, announced it has entered into a know-how agreement with Mayo…

1 year ago

MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update

Company announces participation in BTIG Virtual Biotechnology ConferenceNEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a…

1 year ago

Ambrx to Present Preliminary ARX517 First-in-Human Safety, Efficacy, and Pharmacokinetics Data at ESMO 2023

Presentations represent the first time clinical data regarding ARX517 will be presented at a medical meetingSAN DIEGO, July 28, 2023…

1 year ago

IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center

NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer…

1 year ago